{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:10:46Z","timestamp":1773299446673,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03AG074067"],"award-info":[{"award-number":["R03AG074067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005485","name":"American College of Cardiology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005485","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.amjcard.2022.10.026","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T09:11:53Z","timestamp":1669713113000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1486-7452","authenticated-orcid":false,"given":"Dae Yong","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seokyung","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Doukky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc D.","family":"Samsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sounok","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Nanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1381-5834","authenticated-orcid":false,"given":"Aviral","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2022.10.026_bib0002","doi-asserted-by":"crossref","first-page":"70","DOI":"10.15420\/cfr.2019.6.2","article-title":"Use of renin-angiotensin-aldosterone system inhibitors in older patients with heart failure and reduced ejection fraction","volume":"5","author":"Stolfo","year":"2019","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0003","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0004","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0006","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment With Sacubitril\/Valsartan in patients With advanced heart failure and reduced ejection fraction: A randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0008","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0009","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of Sacubitril\/Valsartan in Japanese patients With chronic heart failure and reduced ejection fraction- results From the PARALLEL-HF study","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0010","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0011","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0012","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jrsm.1460","article-title":"Zero-cell corrections in random-effects meta-analyses","volume":"11","author":"Weber","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0014","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0735-1097(97)00253-2","article-title":"Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients With heart failure fn1","volume":"30","author":"Lang","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1388-9842(03)00162-4","article-title":"Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. The Losartan Pilot Exercise Study Investigators","volume":"5","author":"Matsumori","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0016","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0017","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1161\/01.CIR.100.22.2224","article-title":"Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of candesartan cilexetil in Heart Failure (STRETCH) Investigators","volume":"100","author":"Riegger","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0018","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0167-5273(02)00154-7","article-title":"Heart Failure Valsartan Exercise Capacity Evaluation Study Group. Safety and efficacy of valsartan versus enalapril in heart failure patients","volume":"85","author":"Willenheimer","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0019","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure With reduced ejection fraction: A network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001294","article-title":"Beneficial and harmful effects of sacubitril\/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis","volume":"7","author":"Nielsen","year":"2020","journal-title":"Open Heart"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0023","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1002\/ehf2.12974","article-title":"Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4330\/wjc.v6.i1.4","article-title":"Physiology of natriuretic peptides: the volume overload hypothesis revisited","volume":"6","author":"Arjamaa","year":"2014","journal-title":"World J Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0025","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor\u2013neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0026","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/01.CIR.100.24.2443","article-title":"Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure","volume":"100","author":"Chen","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0027","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/01.CIR.88.2.811","article-title":"Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure","volume":"88","author":"Smits","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0028","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy","volume":"19","author":"D\u00edez","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.026_bib0029","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jamacardio.2019.2223","article-title":"Assessment of national coverage and out-of-pocket costs for Sacubitril\/Valsartan Under Medicare part D","volume":"4","author":"DeJong","year":"2019","journal-title":"JAMA Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:07:21Z","timestamp":1762078041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914922011213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":28,"alternative-id":["S0002914922011213"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.026","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}